Walton D L, Norem C T, Schoen E J, Ray G T, Colby C J
Department of Obstetrics, Kaiser Permanente Medical Care Program, Oakland, Calif 94611-5693, USA.
N Engl J Med. 1999 Dec 30;341(27):2033-8. doi: 10.1056/NEJM199912303412701.
Maternal serum chorionic gonadotropin is measured to screen for fetal chromosomal abnormalities. Whether the results can also be used to predict the risk of complications or an adverse outcome of pregnancy is not known.
We reviewed the medical records of 28,743 girls and women in whom chorionic gonadotropin was measured during the second trimester of pregnancy (between July 1, 1995, and January 31, 1997), seeking information about the complications and outcome of their pregnancies. We excluded girls and women who had preexisting risk factors for complications or an adverse outcome of pregnancy.
Higher serum chorionic gonadotropin concentrations were associated with higher rates of stillbirth (odds ratio for every increase in chorionic gonadotropin of 1 multiple of the median, 1.4; 95 percent confidence interval, 1.1 to 1.9). There was no relation between higher serum chorionic gonadotropin concentrations and the risk of gestational diabetes, premature rupture of membranes or intrauterine growth retardation or small size for gestational age (odds ratio, 1.1; 95 percent confidence interval, 0.9 to 1.2). Higher serum chorionic gonadotropin concentrations were associated with a risk of placental abnormalities (odds ratio, 1.5; 95 percent confidence interval, 1.3 to 1.7), pregnancy-induced hypertension (odds ratio, 1.4; 95 percent confidence interval, 1.3 to 1.5), and preterm delivery without pregnancy-induced hypertension (odds ratio, 1.1; 95 percent confidence interval, 1.0 to 1.2). Inclusion in certain racial or ethnic categories (black, Filipino or Pacific Islander, unknown race or ethnic group, and "other," which included those of Middle Eastern descent and Native Americans) was a better predictor of the risk of an adverse outcome than serum chorionic gonadotropin values.
Measurements of serum chorionic gonadotropin are of little clinical value for predicting the risk of complications and the outcome of pregnancy.
检测孕妇血清绒毛膜促性腺激素以筛查胎儿染色体异常。但其结果是否也可用于预测妊娠并发症风险或不良结局尚不清楚。
我们回顾了1995年7月1日至1997年1月31日妊娠中期检测过绒毛膜促性腺激素的28743名女性的病历,以获取她们妊娠并发症及结局的信息。我们排除了那些妊娠前就存在并发症或不良结局风险因素的女性。
血清绒毛膜促性腺激素浓度越高,死产率越高(绒毛膜促性腺激素每升高1倍中位数,比值比为1.4;95%置信区间为1.1至1.9)。血清绒毛膜促性腺激素浓度升高与妊娠期糖尿病、胎膜早破、胎儿宫内生长受限或小于胎龄儿的风险之间无关联(比值比为1.1;95%置信区间为0.9至1.2)。血清绒毛膜促性腺激素浓度升高与胎盘异常风险(比值比为1.5;95%置信区间为1.3至1.7)、妊娠高血压(比值比为1.4;95%置信区间为1.3至1.5)以及无妊娠高血压的早产风险(比值比为1.1;95%置信区间为1.0至1.2)相关。与血清绒毛膜促性腺激素值相比,属于某些种族或族裔类别(黑人、菲律宾人或太平洋岛民、种族或族裔不明以及“其他”,包括中东血统和美洲原住民)更能预测不良结局风险。
检测血清绒毛膜促性腺激素对预测妊娠并发症风险及结局的临床价值不大。